Related Experiment Video
Updated: Jun 8, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine
Lucas Hill1, Jeffrey Yin1, Nimish Patel2
1University of California San Diego Owen Clinic, Sand Diego, CA; and.
Background:
There is limited data evaluating potential predictors of adherence to injection visits and the impact of late injections on viral suppression in those receiving long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV.
Methods:
A retrospective cohort study was conducted among adult people with HIV receiving LAI CAB/RPV for at least 6 months between May 2021 and August 2023. Data collected included demographics, office visit no-shows 1 year before switching to LAI CAB/RPV, injection visit no-shows, injections outside the dosing window, and virologic outcomes. Cox-proportional hazards regression was performed to evaluate predictors of no-show to injection visits or late injections.
Results:
Included were 287 people with HIV with a median follow-up time (interquartile range) of 450 days (344-548 days). Younger age [HR 0.97 (95% CI: 0.95 to 0.98)] and ≥1 office visit no-show in the year before switching to LAI CAB/RPV [HR 2.03 (1.32 to 3.12]) were associated with having a no-show to an injection visit (32.1%). Male sex assigned at birth [HR 9.18 (1.26 to 66.9)] with a trend toward younger age [HR 0.98 (0.95 to 1.0)] were associated with having a late injection (15.3%). There was no relationship between late injections and having a detectable viral load or virologic failure (n = 3) after switching to LAI CAB/RPV.
Conclusions:
Having office visit no-shows before switching to LAI CAB/RPV was associated with missed injection visits, and younger age was associated with both missed injection visits and late injections. Resources to reduce and manage missed injection appointments need to be considered when implementing LAI CAB/RPV.
More Related Videos
Related Concept Videos
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Factors Influencing Drug Absorption: Presystemic Elimination

